Ming Wang

Dr. Ming Wang

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2024 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
MWMing Wang
Ming Wang
PMPeixuan Men
Peixuan Men
WZWeihe Zhang
Weihe Zhang
JWJing Wu
Jing Wu
YGYuzhen Gu
Yuzhen Gu
HDHongfei Duan
Hongfei Duan
This study aims to estimate the overall in vitro activity of bedaquiline (BDQ) against clinical isolates of Mycobacterium abscessus complex (MABS) and M. avium complex (MAC), considering BDQ as a repurposed drug for non-tuberculous mycobacteria (NTM) infections. We conducted a systematic review of publications in PubMed/ MEDLINE, Web of Science, and Embase up to 15 April 2023. Studies were included if they followed the Clinical and Laboratory Standards Institute (CLSI) criteria for drug susceptibility testing (DST). Using a random effects model, we assessed the overall in vitro BDQ resistance rate in clinical isolates of MABS and MAC. Sources of heterogeneity were analysed using Cochran's Q and the I2 statistic. All analyses were performed using CMA V3.0. A total of 24 publications (19 reports for MABS and 11 for MAC) were included. Using 1 µg/mL and 2 µg/mL as the breakpoint for BDQ resistance, the pooled rates of in vitro BDQ resistance in clinical isolates of MABS were found to be 1.8% (95% confidence interval [CI], 0.7-4.6%) and 1.7% (95% CI, 0.6-4.4%), respectively. In the case of MAC, the pooled rates were 1.7% (95% CI, 0.4-6.9%) and 1.6% (95% CI, 0.4-6.8%) for 1 µg/mL and 2 µg/mL, respectively. This study reports the prevalence of BDQ resistance in clinical isolates of MABS and MAC. The findings suggest that BDQ holds potential as a repurposed drug for treating MABS and MAC infections.

7 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MWMing Wang
Ming Wang
HHhairong huang
hairong huang
HHhairong huang
hairong huang
HDHongfei Duan
Hongfei Duan
Background: The incidence of patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) complicated by chronic pulmonary aspergillosis (CPA) has been increasing. CPA is known to be associated with complex treatment regimens and a poor prognosis. However, data from mainland China remain scarce. Objective: This single-center retrospective study aimed to evaluate the clinical characteristics, risk factors, and prognoses of patients with NTM-PD who were coinfected with CPA. Methods: We conducted a retrospective review of the medical records of 248 patients diagnosed with NTM-PD. Risk factors for CPA were analyzed via multiple logistic regression, followed by survival analysis. Results: Among the 248 patients with NTM-PD, 66 (26.6%) were diagnosed with CPA. Independent risk factors for NTM-PD and CPA coinfection included male sex(OR 2.13, 95% CI:1.03-4.47), dyspnea(OR 27.9, 95% CI:4.24-570), cavity(OR 5.95, 95% CI:2.76-13.9), use of oral corticosteroids(OR 4.28, 95% CI:1.13-16.6), and interstitial lung disease(OR 15.5, 95% CI:1.89-361). The Kaplan-Meier survival curves indicated a significant divergence between the NTM-PD group and the NTM-PD with CPA group (log-rank test, p = 0.00039; HR 2.01, 95% CI:0.66-6.12). Conclusion: In patients with NTM-PD, the presence of concurrent CPA is associated with a marked increase in mortality. Clinicians should maintain a high index of suspicion for CPA to ensure prompt diagnosis and treatment, particularly in high-risk individuals.